The Readout Loud
250: SVB's long biotech shadow, pushy AI algorithms, & Icahn v. Illumina
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
STAT reporter Bob Herman joins us to explain how treatment algorithms powered by artificial intelligence are being used more frequently by Medicare Advantage plans to deny claims, even when continued treatment is medically justified. We’ll also discuss the latest news in the life sciences, including the continued fallout of the run on Silicon Valley Bank, the return of Carl Icahn, and a long-awaited pharmaceutical megadeal.